| US 7,456,168 B2 | ||
| 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones | ||
| Mark Barvian, Ann Arbor, Mich. (US); Richard John Booth, Ann Arbor, Mich. (US); John Quin, III, Ann Arbor, Mich. (US); Joseph Thomas Repine, Ann Arbor, Mich. (US); Derek J. Sheehan, Dexter, Mich. (US); Peter Laurence Toogood, Ann Arbor, Mich. (US); Scott Norman Vanderwel, Ann Arbor, Mich. (US); and Hairong Zhou, Ann Arbor, Mich. (US) | ||
| Assigned to Warner-Lambert Company, Morris Plains, N.J. (US) | ||
| Filed on Apr. 11, 2007, as Appl. No. 11/734,200. | ||
| Application 11/734200 is a continuation of application No. 11/046126, filed on Jan. 28, 2005, granted, now 7,208,489. | ||
| Application 11/046126 is a continuation of application No. 10/345778, filed on Jan. 16, 2003, granted, now 6,936,612. | ||
| Claims priority of provisional application 60/350877, filed on Jan. 22, 2002. | ||
| Prior Publication US 2007/0179118 A1, Aug. 02, 2007 | ||
| Int. Cl. A61K 31/444 (2006.01) | ||
| U.S. Cl. 514—217.06 [514/218; 514/234.2; 514/252.16; 514/264.11; 540/575; 540/600; 544/117; 544/279] | 4 Claims |
1. A method of treating breast cancer in a mammal comprising administering to said mammal an amount of a compound of formula
I:
![]() the dashed line represents an optional bond,
X1, X2, and X3 are independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C8 alkoxy, C1-C8 alkoxyalkyl, CN, NO2, OR5, NR5R6, CO2R5, COR5, S(O)nR5, CONR5R6, NR5COR6, NR5SO2R6, SO2NR5R6, and P(O)(OR5)(OR6); with the proviso that at least one of X1, X2, and X3 must be hydrogen;
n=0-2;
R1 is C1-C6 alkyl,
R2 and R4 are independently selected from hydrogen, halogen, C1-C8 alkyl, C3-C7 cycloalkyl, C1-C8 alkoxy, C1-C8 alkoxyalkyl, C1-C8 haloalkyl, C1-C8 hydroxyalkyl, C2-C8 alkenyl, C2-C8 alkynyl, nitrile, nitro, OR5, SR5, NR5R6, N(O)R5R6, P(O)(OR5)(OR6), (CR5R6)mNR7R8, COR5, (CR4R5)mC(O)R7, CO2R5, CONR5R6, C(O)NR5SO2R6, NR5SO2R6, C(O)NR5OR6, S(O)nR5, SO2NR5R6, P(O)(OR5)(OR6), (CR5R6)mP(O)(OR7)(OR8), (CR5R6)m-aryl, (CR5R6)m-heteroaryl, -T(CH2)mQR5, —C(O)T(CH2)mQR5, NR5C(O)T(CH2)mQR5, and -CR5=CR6C(O)R7;
T is O, S, NR7, N(O)R7, NR7R8W, or CR7R8;
Q is O, S, NR7, N(O)R7, NR7R8W, CO2, O(CH2)m-heteroaryl, O(CH2)mS(O)nR8, (CH2)-heteroaryl, or a carbocyclic group containing from 3-7 ring members, up to four of which ring members are optionally heteroatoms
independently selected from oxygen, sulfur, and nitrogen, provided, however, that there is at least one carbon atom in the
carbocyclic ring and that if there are two or more ring oxygen atoms, the ring oxygen atoms are not adjacent to one another,
wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen,
hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl,
N-hydroxyacetamide, trifluoromethylalkyl, amino, and mono or dialkylamino;
W is an anion selected from the group consisting of chloride, bromide, trifluoroacetate, and triethylammonium;
m=0-6;
R4 and one of X1, X2 and X3 may form an aromatic ring containing up to three heteroatoms independently selected from oxygen, sulfur, and nitrogen, and
optionally substituted by up to 4 groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy,
alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, aminoalkylcarbonyl, trifluoromethyl, trifluoromethylalkyl,
trifluoromethylalkylaminoalkyl, amino, mono- or dialkylamino, N-hydroxyacetamido, aryl, heteroaryl, carboxyalkyl, nitrile,
NR7SO2R8, C(O)NR7R8, NR7C(O)R8, C(O)OR7, C(O)NR7SO2R8, (CH2)mS(O)nR7, (CH2)m-heteroaryl, O(CH2)m-heteroaryl, (CH2)mC(O)NR7R8, O(CH2)mC(O)OR7, (CH2)mSO2NR7R8, and C(O)R7;
R3 is, C1-C8 alkoxy, C3-C7 cycloalkyl, or C3-C7-heterocyclyl;
R5 and R6 independently are hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, arylalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or heteroarylalkyl; or
R5 and R6, when attached to the same nitrogen atom, taken together with the nitrogen to which they are attached, form a heterocyclic
ring containing from 3-8 ring members, up to four of which members can optionally be replaced with heteroatoms independently
selected from oxygen, sulfur, S(O), S(O)2, and nitrogen, provided, however, that there is at least one carbon atom in the heterocyclic ring and that if there are two
or more ring oxygen atoms, the ring oxygen atoms are not adjacent to one another, wherein the heterocyclic group is unsubstituted
or substituted with one, two or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower
alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, aminoalkylcarbonyl, trifluoromethyl, trifluoromethylalkyl,
trifluoromethylalkylaminoalkyl, amino, nitrile, mono- or dialkylamino, N-hydroxyacetamido, aryl, heteroaryl, carboxyalkyl,
NR7SO2R8, C(O)NR7R8, NR7C(O)R8, C(O)OR7, C(O)NR7SO2R8, (CH2)mS(O)nR7, (CH2)m-heteroaryl, O(CH2)m-heteroaryl, (CH2)mC(O)NR7R8, O(CH2)mC(O)OR7, and (CH2)SO2NR7R8;
R7 and R8 are, independently, hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, arylalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or heterarylalkyl; or
R7 and R8, when attached to the same nitrogen atom, taken together with the nitrogen to which they are attached, may form a heterocyclic
ring containing from 3-8 ring members, up to four of which members are optionally heteroatoms independently selected from
oxygen, sulfur, S(O), S(O)2, and nitrogen, provided, however, that there is at least one carbon atom in the heterocyclic ring and that if there are two
or more ring oxygen atoms, the ring oxygen atoms are not adjacent to one another, wherein the heterocyclic group is unsubstituted
or substituted with one, two or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower
alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, aminoalkylcarbonyl, trifluoromethyl, trifluoromethylalkyl,
trifluoromethylalkylaminoalkyl, amino, nitrile, mono- or dialkylamino, N-hydroxyacetamido, aryl, heteroaryl, carboxyalkyl.
|